The IPO prices a pre-revenue biotech at a ~$2.3B market cap (based on 116.6M shares post-offering at $20). Key catalysts to watch: initiation of Phase 3 registrational trial for zolucatetide in desmoid tumors (expected H1 2027), data from ongoing Phase 1/2 trials across multiple indications, and progress of ERG/ARON degrader preclinical programs. The ~$1.0B cash runway into H2 2029 reduces near-term dilution risk but shifts focus to clinical execution.
Executive Summary
Parabilis Medicines priced its IPO of 33,500,000 shares at $20.00/share, raising approximately $623.1 million in gross proceeds (before underwriting discounts and expenses). Additionally, Regeneron is investing $75.0 million in a concurrent private placement at $18.00/share (90% of the IPO price). Combined with a $50.0 million upfront from Regeneron under a May 2026 collaboration, the company expects total pro forma as-adjusted cash of ~$1.02 billion, sufficient to fund operations into H2 2029.
Key Financial Metrics
Key Facts
- 33,500,000 shares offered at $20.00/share, total gross proceeds $670,000,000
- Underwriters' overallotment option of 5,025,000 additional shares
- Regeneron concurrent private placement: 4,166,666 shares at $18.00/share ($75.0M total)
- Net proceeds to company: ~$618.2M from IPO, plus ~$75.0M from private placement
- Pro forma as-adjusted cash position: $1,022,239,000 as of March 31, 2026
- Cash runway extended into H2 2029; funds Phase 3 desmoid tumor trial, pipeline expansion
Financial Impact
$670M gross IPO proceeds + $75M Regeneron PIPE = $745M total gross proceeds; net proceeds ~$693.2M after underwriting and expenses
Risk Factors
- Pre-revenue clinical-stage biotech with no approved products; high risk of trial failure
- Novel modality (Helicons) with unproven regulatory path
- Dilution from 33.5M new shares (28.4% of post-IPO float) and option overhang
- Substantial additional capital likely needed before reaching profitability
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B4 Filing (Primary) | 0001193125-26-265983 |
| Document: 0001193125-26-265983-index-headers.html | 0001193125-26-265983 |
| Document: 0001193125-26-265983-index.html | 0001193125-26-265983 |
| Document: 0001193125-26-265983.txt | 0001193125-26-265983 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 24, 2026 2d ago | Press Release | $24.79 | awaiting T+60 | — | $25.03 (+0.97%) |
Oct 19, 2026 7d ago | Press Release | $25.35 | awaiting T+60 | — | $25.03 (−1.26%) |
Sep 15, 2026 5w ago | 8-K | $36.88 | awaiting T+60 | — | $25.03 (−32.13%) |
Sep 2, 2026 7w ago | 8-K | $40.75 | awaiting T+60 | — | $25.03 (−38.58%) |
Aug 13, 2026 10w ago | 8-K | $35.67 | awaiting T+60 | — | $25.03 (−29.83%) |
Aug 13, 2026 10w ago | Press Release | $35.67 | awaiting T+60 | — | $25.03 (−29.83%) |
Jul 22, 2026 13w ago | Insider Buy | $32.81 $22.75 | ▼ −30.66% | ▼ −34.31% | $25.03 (−23.71%) |
Jun 29, 2026 17w ago | Insider Cluster | $29.19 $33.31 | ▲ +14.11% | ▲ +10.50% | $25.03 (−14.25%) |
Jun 16, 2026 18w ago | Insider Cluster | $26.03 $36.16 | ▲ +38.92% | ▲ +36.23% | $25.03 (−3.84%) |
Jun 15, 2026 18w ago | Insider Cluster | $26.59 $36.88 | ▲ +38.70% | ▲ +36.84% | $25.03 (−5.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers